外泌体在乳腺癌发病中的作用机制

doi:10.3760/cma.j.issn.1673-422X.2016.06.017

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (6): 462-464.doi: 10.3760/cma.j.issn.1673-422X.2016.06.017

外泌体在乳腺癌发病中的作用机制

晏芾，于韶荣，曹海霞，冯继锋

210009 南京医科大学附属江苏省肿瘤医院肿瘤内科

收稿日期:2015-10-17 出版日期:2016-06-08 发布日期:2016-04-27
通讯作者: 冯继锋 E-mail:fjif@vip.sina.com
基金资助:
江苏省自然科学基金（BK20141016、BK20141017）

Mechanism of exosome in the pathogenesis of breast cancer

Yan Fei, Yu Shaorong, Cao Haixia, Feng Jifeng

Department of Medical Oncology, Jiangsu Province Tumor Hospital, Nanjing Medical University, Nanjing 210029, China

Received:2015-10-17 Online:2016-06-08 Published:2016-04-27
Contact: Feng Jifeng E-mail:fjif@vip.sina.com
Supported by:
Natural Science Foundation of Jiangsu Province of China (BK20141016, BK20141017)

摘要/Abstract

摘要： 研究表明外泌体可通过介导细胞间通讯参与乳腺癌的发生发展过程，促进肿瘤转移和耐药，影响肿瘤患者的治疗效果。外泌体与乳腺癌临床分期及预后的关系密切，在乳腺癌早期诊断和生物治疗中具有潜在的临床应用价值，可为乳腺癌的治疗提供新的希望。

关键词: 乳腺肿瘤, 肿瘤转移, 外泌体

Abstract: Researches show that exosome can take park in the development and progression of breast cancer by means of mediating the intercellular communication， which can promote cancer metastasis and drug resistance, thus influencing the treatment effect of patients with cancers. Exosome is closely related with clinical stage and prognosis of breast cancer, which has a potential value in the early diagnosis and biological therapy of breast cancer and provides a new hope for the treatment of breast cancer.

Key words: Breast neoplasms, Neoplasm metastasis, Exosomes

晏芾，于韶荣，曹海霞，冯继锋. 外泌体在乳腺癌发病中的作用机制[J]. 国际肿瘤学杂志, 2016, 43(6): 462-464.

Yan Fei, Yu Shaorong, Cao Haixia, Feng Jifeng. Mechanism of exosome in the pathogenesis of breast cancer[J]. Journal of International Oncology, 2016, 43(6): 462-464.

参考文献

［1］ Lowry MC, Gallagher WM, O′Driscoll L. The role of exosomes in breast cancer［J］. Clin Chem, 2015, 61(12): 1457-1465. DOI: 10.1373/clinchem.2015.240028. ［2］ Villagrasa A, lvarez PJ, Osuna A, et al. Exosomes derived from breast cancer cells, small trojan horses?［J］. J Mammary Gland Biol Neoplasia, 2014, 19(34): 303-313. DOI: 10.1007/s10911-015-9332-5. ［3］ Xu R, Greening DW, Rai A, et al. Highlypurified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and functionally distinct［J］. Methods, 2015, 87: 11-25. DOI: 10.1016/j.ymeth.2015.04.008. ［4］ Sun Y, Liu J. Potential of cancer cellderived exosomes in clinical application: a review of recent research advances［J］. Clin Ther, 2014, 36(6): 863-872. DOI: 10.1016/j.clinthera.2014.04.018. ［5］ Hsu C, Morohashi Y, Yoshimura S, et al. Regulation of exosome secretion by Rab35 and its GTPaseactivating proteins TBC1D10AC［J］. J Cell Biol, 2010, 189(2): 223-232. DOI: 10.1083/jcb.200911018. ［6］ Cai Z, Yang F, Yu L, et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway［J］. J Immunol, 2012, 188(12): 59545961. DOI: 10.4049/jimmunol.1103466. ［7］ Yuyama K, Sun H, Mitsutake S, et al. Sphingolipidmodulated exosome secretion promotes clearance of amyloidbeta by microglia［J］. J Biol Chem, 2012, 287(14): 10977-10989. DOI: 10.1074/jbc.M111.324616. ［8］ Ge Q, Zhou Y, Lu J, et al. miRNA in plasma exosome is stable under different storage conditions［J］. Molecules, 2014, 19(2): 1568-1575. DOI: 10.3390/molecules19021568. ［9］ O′Brien K, Rani S, Corcoran C, et al. Exosomes from triplenegative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells［J］. Eur J Cancer, 2013, 49(8): 1845-1859. DOI: 10.1016/j.ejca.2013.01.017. ［10］ Tang XJ, Sun XY, Huang KM, et al. Therapeutic potential of CART cellderived exosomes: a cellfree modality for targeted cancer therapy ［J］. Oncotarget, 2015, 6(42): 44179-44190. DOI: 10.18632/oncotarget.6175. ［11］ Ostenfeld MS, Jeppesen DK, Laurberg JR, et al. Cellular disposal of miR23b by RAB27dependent exosome release is linked to acquisition of metastatic properties［J］. Cancer Res, 2014, 74(20): 5758-5771. DOI: 10.1158/00085472.CAN-13-3512. ［12］ Thompson CA, Purushothaman A, Ramani VC, et al. Heparanase regulates secretion, composition, and function of tumor cellderived exosomes［J］. J Biol Chem, 2013, 288(14): 10093-10099. DOI: 10.1074/jbc.C112.444562. [13] Wang L, Xie Y, Ahmed KA, et al. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice[J]. Breast Cancer Res Treat, 2013, 140(2): 273-284. DOI: 10.1007/s10549-013-2626-7. ［14］ Higginbotham JN, Demory Beckler M, Gephart JD, et al. Amphiregulin exosomes increase cancer cell invasion［J］. Curr Biol, 2011, 21(9): 779-786. DOI: 10.1016/j.cub.2011.03.043. ［15］ Singh R, Pochampally R, Watabe K, et al. Exosomemediated transfer of miR10b promotes cell invasion in breast cancer［J］. Mol Cancer, 2014, 13：256. DOI: 10.1186/1476-4598-13-256. ［16］ Luga V, Zhang L, ViloriaPetit AM, et al. Exosomes mediate stromal mobilization of autocrine WntPCP signaling in breast cancer cell migration［J］. Cell, 2012, 151(7): 1542-1556. DOI: 10.1016/j.cell.2012.11.024. ［17］ Zhou W, Fong MY, Min Y, et al. Cancersecreted miR105 destroys vascular endothelial barriers to promote metastasis［J］. Cancer Cell, 2014, 25(4): 501-515. DOI: 10.1016/j.ccr.2014.03.007. ［18］ Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2overexpressing exosomes in countering trastuzumabbased therapy［J］. J Cell Physiol, 2012, 227(2): 658-667. DOI: 10.1002/jcp.22773. ［19］ Wei Y, Lai X, Yu S, et al. Exosomal miR221/222 enhances tamoxifen resistance in recipient ERpositive breast cancer cells［J］. Breast Cancer Res Treat, 2014, 147(2): 423-431. DOI: 10.1007/s10549-014-3037-0. ［20］ Zeitzer JM, Nouriani B, Neri E, et al. Correspondence of plasma and salivary cortisol patterns in women with breast cancer［J］. Neuroendocrinology, 2014, 100(23): 153-161. DOI: 10.1159/000367925. ［21］ Lau CS, Wong DT. Breast cancer exosomelike microvesicles and salivary gland cells interplay alters salivary gland cellderived exosomelike microvesicles in vitro［J］. PLoS One, 2012, 7(3): e33037. DOI: 10.1371/journal.pone.0033037. ［22］ Khan S, Bennit HF, Turay D, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer［J］. BMC Cancer, 2014, 14：176. DOI: 10.1186/1471-2407-14-176.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[5]	刘博翰, 黄俊星. 液体活检技术在食管鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 105-108.
[6]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[7]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[8]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[9]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[10]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[11]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[12]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[13]	张渊, 白芷玉, 李琪, 冯勤梅. 外泌体在恶性肿瘤中的研究现状[J]. 国际肿瘤学杂志, 2023, 50(8): 484-488.
[14]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[15]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.

外泌体在乳腺癌发病中的作用机制

Mechanism of exosome in the pathogenesis of breast cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价